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CD8+ T cellHepatitis C virus core (HCVcore) proteinwas expressed in myeloid dendritic cells (DC) from C57/B6 mice (H-
2Kb) by electroporation of HCVcore mRNA to investigate its effect on the ability of DC to prime CD8+ T cells
displaying a T cell receptor speciﬁc for OVA257–264 peptide (SIINFEKL)/H-2Kb complex. Expression of full
length HCVcore191, which is directed to the endoplasmic reticulum (ER) membrane by a C-terminal signal
sequence, but not a truncated variant HCVcore152, which has a wider subcellular localization including the
nucleus, signiﬁcantly reduced surface levels of the H-2Kb/SIINFEKL complex and impaired the ability of DC to
prime naïve CD8+ T cells when they had to process endogenous antigen but not when MHC class I molecules
were loaded directly with SIINFEKL peptide. Exploitation of the MHC class I antigen-processing pathway by
HCVcore191 impairs the ability of DC to stimulate CD8+ T cells and may contribute to the persistence of HCV
infection.
© 2009 Elsevier Inc. All rights reserved.IntroductionDendritic cells (DC) are major determinants of the immune
response (Palucka and Banchereau, 1999) and the major histocom-
patibility complex (MHC) class 1 antigen presentation pathway
within DC plays a pivotal role in generating virus speciﬁc CD8+
cytotoxic T lymphocytes (CTL), which can then eliminate infected
cells (Guermonprez et al., 2002). Given the role of MHC class I-
restricted antigen presentation in the generation of CTL, it is not
surprising that many viruses have developed mechanisms to
interfere with this pathway. Several large DNA viruses encode
proteins whose only function is to interfere with antigen presenta-
tion (Bauer and Tampe, 2002; Hewitt, 2003), whereas small RNA
viruses have limited capacity to develop such genes. Nevertheless,
some RNA virus proteins have been found to be multifunctional
(Mahalingam et al., 2002), such as the Human Immunodeﬁciency
Virus protein Nef, which down-regulates MHC class 1 and CD1d
molecules consequently reducing the visibility of infected cells to
both T cells and NKT cells (Chen et al., 2006; Cho et al., 2005).ased Therapy, Department of
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worldwide as chronic infection may lead to the development of
cirrhosis and Hepatocellular carcinoma (HCC) (Lauer and Walker,
2001). The majority of individuals contracting HCV develop chronic
infection and have only low frequency virus speciﬁc CD4+ and CD8+
T cells (Cucchiarini et al., 2000; Diepolder et al., 1996; Gruener et al.,
2001; Lauer et al., 2004), suggesting that HCV has developed one or
more mechanisms to escape the immune system (Hilleman, 2004).
HCV has been found to interact with a number of receptors that could
facilitate entry into DC including CD81 (Pileri et al., 1998), scavenger
receptor class B (Barth et al., 2008), and DC-speciﬁc ICAM-grabbing
nonintegrin (DC-SIGN) (Lozach et al., 2003). Although the primary
site of HCV infection is the liver, HCV RNA has been detected in
peripheral blood DC (Bain et al., 2001; Goutagny et al., 2003; Navas et
al., 2002; Tsubouchi et al., 2004) but the frequency of DC containing
HCV RNA and the viral levels in DC are extremely low (Bain et al.,
2001; Navas et al., 2002). Accumulating evidence suggests that HCV
subverts DC function (Della Bella et al., 2007; Dolganiuc et al., 2006)
because it was found that myeloid DC from patients with chronic HCV
(Averill et al., 2007; Kanto et al., 2004), and both murine (Hiasa et al.,
1998) and human (Dolganiuc et al., 2003; Sarobe et al., 2002) DC
transduced to express HCV structural proteins exhibit impaired
stimulation of allogeneic T cells. In addition, HCV core protein
(HCVcore) was found to impair DC maturation and reduced their
ability to prime antigen-speciﬁc CD4+ and CD8+ T cell responses
(Sarobe et al., 2003) by downregulation of MHC and co-stimulatory
molecules (Zimmermann et al., 2008). However, not all studies
support a role for HCV inhibiting DC function, since cell culture
Fig. 1. Construction of mRNA expression vector, synthesis of cappedmRNA and transfection of dendritic cells. (A) cDNAs encoding the open reading frames (ORF) of ovalbumin, eGFP,
HCVcore191, or HCVcore152 were inserted downstream of the SP6 promoter and upstream of the mRNA stabilizing sequences (left panel). Linearized vector (1 μg) served as template
in a SP6 mMessage Machine reaction for 3 h at 37 °C. Capped mRNA was extracted, puriﬁed using RNAeasy columns and the quality of the mRNA analyzed by electrophoresis on a
denaturing agarose gel (right panel). (B) Immature murine myeloid DC were mock transfected or transfected with 10 μg eGFP mRNA by electroporation using the Easy-ject plus
system at 300 V, 150 μF and a pulse time of 4 ms in 400 μL of Opti-MEM in a 4 mm electroporation cuvette. DC were analyzed on a FACSCalibur ﬂow cytometer using cell quest
software to determine eGFP expression at 16, 20 and 24 h following transfection. (C) Flow cytometry after propidium iodide staining was used to assess the proportion of dead cells at
12, 24 and 48 h after transfection of DC with 10 μg eGFP mRNA by electroporation.
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Rehermann, 2008) nor impair the function of myeloid DC (Shiina and
Rehermann, 2008).
Understanding the mechanisms by which HCV could modulate the
immune system is fundamental to the development of novel
immunotherapeutic strategies that can induce efﬁcient cellular
immune responses in chronically infected patients. Therefore, we
investigated whether HCVcore modulates the ability of the DC to
process and present a model antigen, chicken Ovalbumin (OVA), in
associationwithMHC class I molecules to CD8+ Tcells. We found that
full length HCVcore (HCVcore191) subverts the MHC class I antigen-
processing pathway in DC, resulting in reduced expression of MHC/peptide complex on the surface of DC and an impaired ability to
stimulate CD8+ T cells.
Results
Transfection of myeloid dendritic cells by electroporation of mRNA
Theyield of each SP6mMessageMachine reactionwas around20 μg
of capped mRNA from 1 μg of linear DNA template. Transcripts were
extracted using RNAeasy columns (Qiagen, Crawley, UK) and the
quality of the mRNA conﬁrmed by denaturing agarose gel before use
(Fig. 1). Electroporation of eGFP mRNA into myeloid DC, derived from
Fig. 2. Effect of HCVcore191 on the function of murine myeloid DC in allogeneic mixed
lymphocyte reaction. Myeloid DC (1× 105 per well), derived from C57/B6 mice (H-2b),
16 h after transfectionwith 10 μg HCVcore191 mRNA,10 μg OVAmRNA,10 μg eGFPmRNA
or mock transfection (Control) were compared in their ability to stimulate proliferation
of allogeneic C3H/HeN (H-2k) T cells (5×105 per well, in replicates of 5), before and
after enrichment for CD8+ cells by depletion of CD4+ cells using anti-CD4-MACS
beads. After 4 days of co-culture, 0.5 μCi of 3H-Thymidine was added to each well and
3H-Thymidine incorporation measured after 16 h. T cells alone and DC alone are shown
for comparison. ⁎pb0.05 and ⁎⁎pb0.01 comparing control DC to DC transfected with
HCVcore191 mRNA; error bars reﬂect sd. The data shown are representative of three
independent experiments.
Fig. 3. Effect of HCVcore on the function of human monocyte-derived DC in allogeneic
mixed lymphocyte reaction. Human monocyte-derived DC (1× 105 per well), 16 h after
transfection with 10 μg HCVcore191 mRNA or 10 μg HCVcore152 mRNA or mock
transfection (Control DC) and maturation with LPS were compared in their ability to
stimulate proliferation of allogeneic T cells (5×105 per well in triplicates). HCVcore
proteins were also expressed as fusion proteins with ubiquitin (A76) in order to target
the linked protein for degradation by the proteasome. After 4 days of co-culture, 0.5 μCi
of 3H-Thymidine was added to each well and 3H-Thymidine incorporation measured
after 16 h. Tcells alone and DC alone are shown for comparison. ⁎⁎pb0.01 comparing DC
transfected with HCVcore191 mRNA to other DC; error bars reﬂect sd. The data shown
are representative of three independent experiments.
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assessed by FACS analysis of eGFP positive cells, and peak expression of
eGFP was seen at 16 h (Fig. 1). We found 20 μg mRNA as the optimal
dose for expression of eGFP in DC by electroporation (data not shown).
The transfection efﬁciency of eGFP mRNA into myeloid DC was
unaffected by co-transfection with OVA mRNA or HCVcore191 mRNA
(data not shown). After electroporation, ﬂow cytometry analysis
showed that the proportion of dead cells, as assessed by propidium
iodide staining, increased with time from 0.4% at 12 h to 12.6% at 48 h
(Fig. 1). These ﬁndings conﬁrm previous observations that electro-
poration of mRNA is an efﬁcient method of expressing proteins in
myeloid DC with remarkably low cell toxicity (Van Tendeloo et al.,
2001). Based on these results, in subsequent experiments myeloid DC
were used at 16 h after electroporation with mRNA.
Effect of HCVcore191 on the function of murine DC and human
monocyte-derived DC in allogeneic mixed lymphocyte reaction
Myeloid DC, derived from C57/B6 mice (H-2b) that had been
transfected with 10 μg HCVcore191 mRNA and matured in LPS induced
signiﬁcantly less proliferation of allogeneic C3H/HeN (H-2k) T cells
compared to mock transfected DC (pb0.01) or DC transfected with
either 10 μg eGFP mRNA (pb0.01) or 10 μg OVA mRNA (pb0.05) (Fig.
2). Depletion of CD4+ cells from the responder T cell population,
using anti-CD4-MACS beads (Miltenyi Biotec, Bergisch Gladbach,
Germany), did not restore the ability of DC transfected with
HCVcore191 mRNA to stimulate allogeneic T cell proliferation, indicat-
ing that the mechanism of inhibition of CD8+ T cell proliferation by
HCVcore191 was independent of CD4+ T cells (Fig. 2).
In order to ensure that the effect of HCVcore on DC function is
applicable to human cells, we transfected humanmonocyte-derivedDC
with HCVcore191 mRNA prior to maturation and found they induced
signiﬁcantly less proliferation in allogeneic Tcells, harvested fromblood
donated by a patient with hemochromatosis undergoing maintenance
venesection, compared to control transfected DC (pb0.01) (Fig. 3).
However, the inhibition of DC function was not apparent when
HCVcore191 was targeted for rapid degradation by the proteasome,
indicating that the immunosuppressive effect of HCVcore191 on DCwas
dependent on the presence of theHCVprotein rather than due to a non-
speciﬁc effect of the mRNA electroporation process. Importantly,HCVcore152, either alone or as a fusion protein with ubiquitin, did not
inhibit the stimulation of allogeneic T cell proliferation by DC (Fig. 3).
Transfection with mRNA, irrespective of the encoded sequence,
followed by maturation with LPS up-regulated the expression of HLA
class II, the co-stimulatory molecules, CD80 and CD86, and the
maturation marker CD83 to similar levels (data not shown).
Inhibition of MHC class I-restricted antigen presentation by myeloid
dendritic cells expressing HCV core
Optimal stimulation of the B3Z T cell hybridoma requires that the
OVA257–264 peptide (SIINFEKL) is presented by APC expressing H2-Kb,
whether it is added exogenously or synthesized endogenously from
OVA polypeptide (Shastri and Gonzalez, 1993). The level of activation
of the B3Z T cell hybridoma, as measured by induction of the reporter
gene product β-galactosidase, increases in proportion to the expres-
sion of H-2Kb/SIINFEKL by the APC and, hence, can be used to quantify
H-2Kb/SIINFEKL levels on the surface of DC (Galea-Lauri et al., 2004).
Electroporation of myeloid DC, derived from C57/B6 mice, with 20 μg
OVA mRNA resulted in quantiﬁable expression of H-2Kb/SIINFEKL, as
evidenced by activation of the B3Z T cell hybridoma (Fig. 4), but
increasing the amount of transfected OVA mRNA above 20 μg did not
augment the level of B3Z activation (data not shown).
To examine the effect of HCVcore on the presentation of H-2Kb/
SIINFEKL to the B3Z T cell hybridoma, myeloid DC derived from C57/
B6micewere transfected with 20 μg OVAmRNA alone or with 10 μg of
HCVcore191 mRNA, HCVcore152 mRNA, or eGFP mRNA. Co-transfection
of DC with HCVcore191 mRNA resulted in a signiﬁcantly lower level of
activation of the B3Z T cell hybridoma compared to DC transfected
with OVA mRNA alone (pb0.05) (Fig. 4), indicating that expression of
HCVcore191 led to a reduction in levels of H-2Kb/SIINFEKL complex on
the DC plasma membrane. The inhibitory effect of HCVcore191 on the
Fig. 5. Inhibition of MHC class I-restricted antigen presentation to naïve OT-1 CD8+
lymphocytes by myeloid dendritic cells expressing HCV core. After 5 days of co-culture,
cells were pulsed with 0.5 μCi of 3H-Thymidine and 3H-Thymidine incorporation was
measured after 16 h using a Matrix 9600 beta-counter. A) Responder lymphocytes
(5× 104 per well, in replicates of 5) from OT-1 mice, following red cell and B cell
depletion, were incubated in 200 μL X-Vivo with increasing numbers of mocked
transfected DC (control), DC transfected with 20 μg OVA mRNA or DC pulsed with 1 nM
SIINFEKL peptide. ⁎pb0.05 comparing DC transfected with OVA mRNA to DC pulsed
with SIINFEKL. B) Proliferation of OT-1 lymphocytes (5×104 per well, in replicates of 5)
was assessed after exposure to DC (1×104 per well), transfected with 20 μg OVA mRNA
alone or co-transfected with either 10 μg HCVcore191 mRNA or 10 μg eGFP mRNA, or
mock transfected (Control DC); or DC pulsed with 1 nM SIINFEKL peptide alone or after
transfectionwith 10 μg HCVcore191 mRNA. OT-1 T cells alone are shown for comparison.
⁎pb0.05 comparing DC co-transfected with HCVcore191 mRNA to DC co-transfected
with eGFP mRNA and pb0.01 to DC transfected with OVA mRNA alone. The data shown
are representative of two independent experiments.
Fig. 4. Inhibition of MHC class I-restricted antigen presentation to B3Z T cell hybridoma
by myeloid dendritic cells expressing HCV core. Induction of the reporter gene product
β-galactosidase in the B3Z T cell hybridoma was used to quantify expression of H-2Kb/
SIINFEKL on the surface myeloid DC, derived from C57/B6 mice. DC (1×104), 16 h after
transfection, were co-cultured with B3Z cells (1×105 per well, in replicates of 6) in
200 μL of phenol red free RPMI medium, for 16 h. Then 150 μL of mediumwas replaced
with 150 μL PBS containing 5 mM ONPG and 0.5% Nonidet P-40. Cells were left at 37 °C
for 2 h before the optical density of the plates was read at a wavelength of 415 nM using
an MRX microplate reader. In (A) DC were transfected with 20 μg OVA mRNA alone or
with either 10 μg HCVcore191 mRNA, 10 μg HCVcore152 mRNA, or 10 μg eGFP mRNA,
mocked transfected DC are shown for comparison; and in (B) DCwere pulsed with 1 nM
SIINFEKL peptide alone or after transfection of DC with 10 μg HCVcore191 mRNA. B3Z T
cells alone and mocked transfected DC are shown for comparison. ⁎⁎pb0.01 comparing
DC transfected with HCVcore mRNA to other DC; error bars reﬂect sd. The data shown
are representative of four independent experiments.
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was not simply due to a non-speciﬁc effect of co-transfection of
another mRNA species because co-transfection of DC with 10 μg eGFP
mRNA had no effect on the ability of the DC to process OVA
polypeptide and present H-2Kb/SIINFEKL to B3Z cells. In marked
contrast to the effect of full length HCVcore191, co-transfection of DC
with 10 μg HCVcore152 mRNA led to increased activation of the B3Z T
cell hybridoma compared to DC transfected with 20 μg OVA mRNA
alone (Fig. 4), indicating that expression of HCVcore152 led to an
increase in levels of H-2Kb/SIINFEKL complex on the DC plasma
membrane.
Although HCVcore191 inhibited MHC class I antigen presentation
by DC processing endogenous antigen, it had no effect on the ability of
DC to express H-2Kb/SIINFEKL complex at the cell surface when the
DC were loaded with SIINFEKL peptide because transfection of DC
with 10 μg HCVcore191 mRNA had no effect on the level of activation of
the B3Z T cell hybridoma by DC pulsed with 1 nM SIINFEKL peptide
(Fig. 4). These ﬁndings indicate that DC transfected with 10 μg
HCVcore191 mRNA are still competent for T cell activation but theMHC
class I molecules being transported to the plasma membrane are not
associated with peptide because the HCVcore191 is inhibiting one or
more components of the MHC class I antigen-processing pathway.
The capacity of OVA mRNA transfected myeloid DC, derived from
C57/B6 mice, to present H-2Kb/SIINFEKL was also assessed by their
ability to stimulate proliferation in naïve Tcells fromOT-1mice, which
have a transgenic T cell receptor speciﬁc for the immunodominant
OVA257–264 peptide (SIINFEKL) expressed in the context of the MHC
class I molecule H-2Kb. DC transfected with 20 μg OVA mRNA weremore efﬁcient at stimulating OT-1 T cell proliferation than DC pulsed
with 1 nM SIINFEKL peptide (Fig. 5).
DC co-transfected with 10 μg HCVcore191 mRNA induced a
signiﬁcantly lower level of proliferation of OT-1 lymphocytes
compared to DC co-transfected with 10 μg eGFP mRNA (pb0.05) or
DC transfected with 20 μg OVA mRNA alone (pb0.01), whereas
expression of HCVcore191 had no effect on the ability of DC pulsedwith
1 nM SIINFEKL to stimulate the proliferation of OT-1 T cells (Fig. 5).
Discussion
In this study, using electroporation of mRNA to express HCVcore
proteins, we demonstrate that full length HCVcore191 inhibits the
ability of both myeloid murine DC and human monocyte-derived DC
to stimulate proliferation of allogeneic T cells. The immunosuppres-
sive effect of HCVcore191 on DC was dependent on the presence of
HCVcore protein rather than a non-speciﬁc effect of transfection of
HCV mRNA because DC function was not inhibited when HCVcore191
5J. O'Beirne et al. / Virology 389 (2009) 1–7protein was expressed as a fusion protein with ubiquitin, which
targets the linked protein for degradation by the proteasome
(Michalek et al., 1993). Other authors have suggested that the
inhibitory effect of HCVcore on DC function may be due to the
induction of CD4+ CD25+ T regulatory cells (Boettler et al., 2005;
Rushbrook et al., 2005) but this mechanism is unlikely to explain our
results because removal of CD4+ T cells had no inﬂuence on the
ability of HCVcore191 to inhibit the stimulation of allogeneic CD8+ T
cells by DC.
More relevant to patients with chronic HCV infection, who display
only low frequency virus speciﬁc CD8+ T cell responses directed
against a limited repertoire of epitopes (Gruener et al., 2001; Lauer et
al., 2004), this study showed that HCVcore191 inhibited the ability of
DC to prime naïve OT-1 T cells, which display a T cell receptor speciﬁc
for the H-2Kb/SIINFEKL complex, but only when the DC had to process
endogenous OVA polypeptide and not when MHC class I molecules
were loaded directly with SIINFEKL peptide. Inhibition of MHC class I-
restricted antigen presentation by HCVcore191 was conﬁrmed when
we used activation of the B3Z T cell hybridoma to quantify expression
of the H-2Kb/SIINFEKL complex on the cell surface of the antigen
presenting cells. Again, we found that HCVcore191 profoundly
inhibited the ability of DC to generate expression of the H-2Kb/
SIINFEKL complex on the cell surface when the DC were required to
process endogenous OVA polypeptide but, importantly, HCVcore191
did not reduce surface levels of the H-2Kb/SIINFEKL complex when
theMHC class I molecules were loaded directly with SIINFEKL peptide.
Previous studies found that expression of HCVcore with envelope
proteins reduced the surface levels of MHC class I molecules
(Zimmermann et al., 2008) and it was postulated that this was due
to HCV proteins blocking transportation of MHC class I molecules to
the cell surface during maturation rather than inhibiting their
production (Hiasa et al., 2004; Tardif and Siddiqui, 2003). Our data
also indicate that HCVcore191 did not impair the generation or
accessibility of MHC class I molecules in DC because they were readily
available to bind exogenously loaded SIINFEKL peptide. Rather, the
ﬁndings indicate that HCVcore191 inhibited one or more components
of the MHC class I antigen-processing pathway, because HCVcore191
inhibited the expression of the H-2Kb/SIINFEKL complex only when
the DC had to process endogenous OVA polypeptide. It is recognized
that MHC class I molecules not loaded with peptide epitope are
rapidly recycled from the cell surface unless stabilized by the addition
of exogenous peptide.
In contrast to the immunosuppressive effect of HCVcore191 on DC
function, HCVcore152, a variant truncated by 39 amino acid residues at
the carboxyl end, consistently failed to inhibit both MHC class I
antigen presentation of the OVA epitope, SIINFEKL, bymurinemyeloid
DC and the stimulation of allogeneic T cells by human monocyte-
derived DC. The mechanism by which HCVcore191 interferes with the
MHC class I antigen-processing and presentation pathway in DC is
unknown but its subcellular localization to the ER membrane places it
in the appropriate compartment to interfere with the function of
Transporter for Antigen Processing (TAP) or assembly of the MHC
class I/peptide complex. HCV core protein was shown to interact with
MHC class I molecules in a study of soluble hepatocyte proteins but
the binding sites were not studied (Kang et al., 2005). When released
from the nascent viral polypeptide by host proteases, HCVcore191 is
directed to the ER membrane by a C-terminal hydrophobic signal
sequence. Subsequently, cleavage between amino acids 179 and 180
by an intramembrane signal peptide peptidase (SPP) generates
mature HCVcore (Okamoto et al., 2008; Targett-Adams et al., 2008;
Weihofen et al., 2002), which is the predominant form detected in
cultured cells following transfection with a HCVcore expression
plasmid and in viral particles obtained from sera of patients with
HCV infection. The mature core protein is also localized primarily to
the ER (Okamoto et al., 2004) with its N-terminus lying in the cytosol
(Barba et al., 1997; Santolini et al., 1994) but further processing by anunidentiﬁed protease releases a C-terminal truncated protein
(HCVcore152) that has a wider subcellular localization being detected
in the nucleus, ER and mitochondrial outer membrane (Lo et al., 1995;
Moorman et al., 2003; Yasui et al., 1998). The region of HCVcore191
mediating inhibition of MHC class I antigen-processing is unknown
and further work is required to determinewhether the lack of effect of
HCVcore152 on DC function is due to deletion of the active domain or
to differences in the subcellular trafﬁcking of the HCVcore isoforms
resulting in low levels of HCVcore152 being retained in the ER
membrane.
In summary, this study showed that expression of HCVcore191 in
DC not only inhibited the stimulation of allogeneic T cells but also
down-regulated cell surface expression of MHC class I/peptide
complex when DC had to process endogenous antigen but not when
MHC class I molecules were loaded directly with peptide. Exploitation
by full length HCVcore of the MHC class I antigen-processing pathway
in DC impairs their ability to stimulate naïve CD8+ T cells and may
contribute to the persistence of HCV infection.
Patients with HCV infection retain the ability to respond to the
majority of antigenic stimuli but it is recognized that they demon-
strate poor CD8+ T cell responses against HCV-derived antigens
(Gruener et al., 2001; Lauer et al., 2004). Since the frequency of DC
containing HCV RNA is very low (Bain et al., 2001; Navas et al., 2002),
it is tempting to speculation that the virus only perturbs antigen
presentation by this small population of DC and hence interferes with
the generation of HCV-speciﬁc T cells without disturbing the immune
response to antigen presented by the majority of uninfected DC.
Materials and methods
Mice and cell lines
C57/B6 female mice (H-2b) and C3H/HeN (H-2k) mice were
purchased from Harlan, Oxford, UK. OT-1 transgenic B6 mice were a
kind gift from Dr. Alistair Noble. OT-1 T cells recognize the naturally
processed, immunodominant, OVA peptide 257–264 (SIINFEKL) in
association with the murine MHC-I molecule H-2Kb. The B3Z T cell
hybridoma, a fusion of B3 cells (a Vb5 expressing CTL clone speciﬁc for
H-2b/OVA) and Z8 cells (NFAT-lacZ inducible derivative of BW5147),
express a T cell receptor (TCR) for H-2Kb/SIINFEKL (Shastri and
Gonzalez, 1993) and were cultured in RPMI supplemented with 10%
fetal calf serum (FCS) in the presence of penicillin and streptomycin at
37 °C and 5% CO2.
Preparation of murine dendritic cells
Immature myeloid dendritic cells were cultured from the bone
marrow precursors of 3–6 week old female C57/B6 mice using a
method derived from Lutz (Lutz et al., 1999). Bone marrow cells were
plated at 2×105/ml in 10 ml of X-Vivo (Biowhittaker, Wokingham,
UK) in 100 mm bacteriological culture plates and cultures were
initiated with 10 ng/ml rmGM-CSF and 10 ng/ml rmIL-4 (both from
R&D systems, Abingdon, Oxon, UK). On day 3 the cultures were fed
with a further 10 ml of X-Vivo and further rmGM-CSF and rmIL-4
(ﬁnal concentration 10 ng/ml). On day ﬁve of culture, the plates
received a further 5 ml of X-Vivo supplementedwith rmGM-CSF (ﬁnal
concentration 5 ng/ml); by day six, large clumps of semi-adherent
cells representing immature DC were apparent, these were harvested
on day six or seven of culture and used in immunological assays.
Preparation of human dendritic cells
Fresh heparinized, peripheral blood samples were obtained from
normal subjects, according to a protocol approved by The Kings
College Hospital Ethical Committee (LREC Protocol number 01/248).
Informed, written consent was obtained and the study was performed
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of Helsinki. Human DC were derived from peripheral blood mono-
cytes, essentially as described (Romani et al., 1996). Peripheral blood
mononuclear cells (PBMC) were separated by density gradient
centrifugation, washed and adherent cells (7×106 per well of 6-well
plates; Nunc, UK) were cultured at 37 °C for 7 days in X-Vivo, 1%
autologous plasma, and 800 U/ml GM-CSF plus 500 U/ml Interleukin-
4 (IL-4) (both from R&D Systems, Abingdon, UK) with cytokine
replenishment after 3 days.
Immature monocyte-derived DC were transfected with mRNA by
electroporation in 400 μL of X-Vivo with no supplements using the
Easy-ject plus system (Equibio, Ashford, UK) at 300 V and 150 μF and a
pulse time of 4ms, as previously described (VanTendeloo et al., 2001).
After electroporation, DC were resuspended in 3 ml of X-Vivo with
antibiotics and rested for 1 h before maturation with LPS (100 ng/ml)
(Sigma, UK) for 16 h. The cells were washed 3 times with warm
medium before use.
DC were immunophenotyped after re-suspension in PBA (phos-
phate buffered saline (PBS), 0.1% BSA, 0.02% sodium azide) and
incubation for 20 min with ﬂurochrome labeled antibodies. After two
washes in PBA, the cells were ﬁxed in 1% paraformaldehyde in PBS.
Analysis was performed using a FACScan ﬂow cytometer with Cell
Quest software (Becton Dickinson, Cowley, Oxford, UK). Phycoery-
thrin (PE)-conjugated antibodies used were anti-CD14 (Serotec,
Kidlington, Oxford, UK), and anti-CD83 (Immunotech, Luton, Bed-
fordshire, UK). Fluorescein isothiocyanate (FITC)-conjugated antibo-
dies were anti-CD80, anti-CD86 (Pharmingen, Cowley, Oxford, UK),
anti-CD1a and anti-HLA Class II (Dako, Ely, Cambridgeshire, UK).
Isotype speciﬁc controls were from Becton Dickinson.
Construction of the mRNA expression vector
An mRNA expression vector was constructed on the backbone of
the PGEM 5Z(+) vector (Promega, Southampton, UK). The original
multiple cloning cassette was replaced to facilitate the insertion of
new sequences: we introduced the 3′ region of the human alpha-
globin gene followed by a 76 nucleotide poly-A sequence to increase
the intracellular stability of mRNA transcripts (Weiss and Liebhaber,
1995). Subsequently, cDNA sequences encoding the open reading
frames of OVA, enhanced green ﬂuorescent protein (eGFP), the 191
amino acid full length HCV core protein (HCVcore191) or a truncated
variant encoding the N-terminal 152 amino acid HCV core protein
(HCVcore152) were inserted between Nhe1 and Age1 sites, down-
stream of the SP6 promoter site of PGEM5Z and upstream of the stop
codon and mRNA stabilizing sequences (Fig. 1). The sequences
encoding OVA and eGFP were generated by PCR from plasmid
templates supplied by Dr. Joop Gaken and Dr. Paul Richardson,
respectively. HCVcore191 and HCVcore152 were ampliﬁed by RT-PCR
from the blood of a patient chronically infected with HCV genotype 1a.
Attaching the 76-amino acid ubiquitin to a protein marks it for
polyubiquitinylation and subsequent transfer to the proteasome for
degradation (Michalek et al., 1993). However, ubiquitin containing a
G76 residue immediately N-terminal to the targeted protein is
recognized by speciﬁc intracellular proteases, which efﬁciently cleave
it after the G76 residue, releasing the ubiquitin tag and preventing
polyubiquitinylation, whereas mutation of ubiquitin G76 to A76
diminishes the rate of cleavage of fusion protein by N90% while still
permitting the fused ubiquitin to serve as a substrate for polyubiqui-
tinylation (Jonnalagadda et al., 1989). We, therefore, modiﬁed the
expression plasmid by inserting ubiquitin (A76) N-terminal to, and in
frame with the HCVcore proteins (Fig. 3). The cDNA encoding a
monomer of human ubiquitin (A76) was ampliﬁed by PCR from
human genomic DNA; a 5′ primer supplied an ATG start codonwith an
appropriate Kozak sequence, and the 3′ primer changed the C-
terminal amino acid from glycine (G76) to alanine (A76), for reasons
explained above. All vectors were sequenced to conﬁrm authenticity.In vitro transcription of mRNA
The vectors were linearized using a SnaB1 restriction site, which
was immediately downstream of the poly-A sequence, and the
resulting linear DNA was isolated by gel extraction. Following the
manufacturers' instructions, the linear DNA (1 μg) served as template
in an SP6 mMessage Machine reaction (Ambion, Huntingdon, UK).
After 3 h at 37 °C the capped mRNA was extracted and puriﬁed using
RNAeasy columns (Qiagen, Crawley, UK). Transcript quality was
scrutinized on denaturing agarose gels before use.
Transfection of murine DC with mRNA transcripts
Immature DC were transfected with 20 μg OVA mRNA alone or
with 10 μg of HCVcore or eGFPmRNA by electroporation, as previously
described (Van Tendeloo et al., 2001). After electroporation, cells were
resuspended in 3 ml of X-Vivo with antibiotics and 5 ng/ml rmGM-
CSF. One hour after electroporation with mRNA the DC were matured
with LPS (100 ng/ml) (Sigma, UK) for 16 h. For experiments involving
peptide pulsing, DC were pulsed for 6 h with 1 nM SIINFEKL peptide
(Proimmune, UK) prior to the immunological assays. All DC were
irradiated prior to use in the immunological assays.
Allogeneic mixed lymphocyte reaction
For allogeneic mixed lymphocyte reactions, matured, irradiated,
DC transfected with mRNA were co-cultured in 200 μL of X-Vivo with
red cell depleted splenocytes from C3H/HeN mice. After 4 days of co-
culture, T cell proliferationwas measured by 3H-Thymidine incorpora-
tion using a Matrix 9600 beta-counter (Packard, Pangbourne, UK). In
some experiments, T cells were enriched for CD8+ cells by depletion
of CD4+ cells using anti-CD4-MACS beads (Miltenyi Biotec, Bergisch
Gladbach, Germany).
Measurement of H-2Kb/SIINFEKL levels on DC by B3Z T cell colorimetric
assay
We used induction of the reporter gene β-galactosidase in the B3Z
T cell hybridoma to quantify expression of H-2Kb/SIINFEKL on the
surface myeloid DC transfected with OVA mRNA or loaded with
SIINFEKL peptide, as previously described (Galea-Lauri et al., 2004).
Stimulation of naïve OT-1 lymphocytes
We used OT-1 lymphocytes to test the ability of DC to activate
naïve CD8+ T cells. Lymphocytes, isolated from both the spleens and
lymph nodes of OT-1 mice, were ﬁrst depleted of red cells, using red
cell lysis buffer (Sigma), and then of B cells, using mouse pan B cell-
speciﬁc beads (Dynabeads, Invitrogen), according to the manufac-
turer's instructions. OT-1 lymphocyte activation by antigen loaded DC
was assessed, as previously described (Galea-Lauri et al., 2004).
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